So far, the effects of chemotherapy on CBC risk in BRCA1/2 mutation carriers have been investigated only in a limited number of studies [1,10,11]; in only one study the effects of different chemotherapeutic agents on CBC risk were investigated, though with BRCA1 and BRCA2 mutation carriers combined [11]. The gene discussed is BRCA1; the disease is complete blood cell count.